AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of 3.70 million. The enterprise value is 2.67 million.
| Market Cap | 3.70M |
| Enterprise Value | 2.67M |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.30% |
| Shares Change (QoQ) | +10.99% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 61.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.77 |
| PB Ratio | -2.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.15 |
| EV / Sales | 15.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.18 |
Financial Position
The company has a current ratio of 0.44
| Current Ratio | 0.44 |
| Quick Ratio | 0.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -33.80 |
Financial Efficiency
Return on equity (ROE) is -388.69% and return on invested capital (ROIC) is -196.60%.
| Return on Equity (ROE) | -388.69% |
| Return on Assets (ROA) | -88.30% |
| Return on Invested Capital (ROIC) | -196.60% |
| Return on Capital Employed (ROCE) | 2,132.90% |
| Revenue Per Employee | 7,727 |
| Profits Per Employee | -787,273 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 991,855 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of 170,000 and -17.32 million in losses. Loss per share was -0.31.
| Revenue | 170,000 |
| Gross Profit | 139,000 |
| Operating Income | -19.77M |
| Pretax Income | -17.32M |
| Net Income | -17.32M |
| EBITDA | -19.53M |
| EBIT | -19.77M |
| Loss Per Share | -0.31 |
Balance Sheet
The company has 3.98 million in cash and 2.94 million in debt, giving a net cash position of 1.04 million.
| Cash & Cash Equivalents | 3.98M |
| Total Debt | 2.94M |
| Net Cash | 1.04M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.32M |
| Book Value Per Share | -0.02 |
| Working Capital | -5.36M |
Cash Flow
In the last 12 months, operating cash flow was -14.89 million and capital expenditures -18,000, giving a free cash flow of -14.91 million.
| Operating Cash Flow | -14.89M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -14.91M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 81.76% |
| Operating Margin | -11,630.59% |
| Pretax Margin | -10,188.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.30% |
| Shareholder Yield | -15.30% |
| Earnings Yield | -467.95% |
| FCF Yield | -402.73% |
Stock Splits
The last stock split was on June 11, 2019. It was a reverse split with a ratio of 0.022727273.
| Last Split Date | Jun 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.022727273 |
Scores
AIM ImmunoTech has an Altman Z-Score of -76.58. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -76.58 |
| Piotroski F-Score | n/a |